Search Results - "Tasker, Sybil A."

This result is not displayed to guests.
Login for full access.

Reimmunization with 23-Valent Pneumococcal Vaccine for Patients Infected with Human Immunodeficiency Virus Type 1: Clinical, Immunologic, and Virologic Responses.

Authors: Tasker, Sybil A. Wallace, Mark R. Rubins, Jeffrey B. et al.

Source: Clinical Infectious Diseases. 3/15/2002, Vol. 34 Issue 6, p813. 9p. 3 Charts, 3 Graphs.

The Changing Economics of HIV Care.

Authors: Wallace, Mark R. Tasker, Sybil A. Shinohara, Y. Todd et al.

Source: AIDS Patient Care & STDs. Jan2001, Vol. 15 Issue 1, p25-29. 5p. 4 Charts.

Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial.

Authors: Tasker, Sybil A. Treanor, John J. Tasker, S A et al.

Source: Annals of Internal Medicine. 09/21/99, Vol. 131 Issue 6, p430-433. 4p. 2 Charts.

Unintended Smallpox Vaccination of HIV-1--Infected Individuals in the United States Military.

Authors: Tasker, Sybil A. Schnepf, Glenn A. Lim, Matthew et al.

Source: Clinical Infectious Diseases. 5/1/2004, Vol. 38 Issue 9, p1320-1322. 3p.

Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials.

Authors: Langley, Joanne M. Sadarangani, Manish Ockenhouse, Christian et al.

Source: Vaccine. Mar2026, Vol. 75, pN.PAG-N.PAG. 1p.

Ensuring Participant Safety and Trial Integrity With Clinical Trials Oversight.

Authors: Godfrey, Catherine Payton, Manizhe Tasker, Sybil et al.

Source: JAIDS: Journal of Acquired Immune Deficiency Syndromes. 1/1/2014 Supplement 1, Vol. 65, pS40-S43. 4p.

Health Care Workers and Researchers Traveling to Developing-World Clinical Settings: Disease Transmission Risk and Mitigation.

Authors: Kortepeter, Mark G. Seaworth, Barbara J. Tasker, Sybil A. et al.

Source: Clinical Infectious Diseases. 12/1/2010, Vol. 51 Issue 11, p1298-1305. 8p.

Meningococcal Pneumonia: Characterization and Review of Cases Seen Over the Past 25 Years.

Authors: Winstead, Jonathan M. McKinsey, David S. Tasker, Sybil et al.

Source: Clinical Infectious Diseases. 1/1/2000, Vol. 30 Issue 1, p87. 8p.

A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates.

Authors: Mueller, Steffen Stauft, Charles B. Kalkeri, Raj et al.

Source: Vaccine. Mar2020, Vol. 38 Issue 14, p2943-2948. 6p.

Multidrug-resistant Tuberculosis in Military Recruits.

Authors: Freier, Grace Wright, Allen Nelson, Gregory et al.

Source: Emerging Infectious Diseases. May2006, Vol. 12 Issue 5, p760-762. 3p.

Bartonella henselae Serostatus is not Correlated with Neurocognitive Decline in HIV Infection.

Authors: Wallace, Mark R. Persing, David H. McCutchan, J. Allen et al.

Source: Scandinavian Journal of Infectious Diseases. Aug2001, Vol. 33 Issue 8, p593-595. 3p.

Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease.

Authors: Bernstein, David I. Flechtner, Jessica B. McNeil, Lisa K. et al.

Source: Vaccine. Jun2019, Vol. 37 Issue 26, p3443-3450. 8p.

Effects of Different Doses of GEN-003, a Therapeutic Vaccine for Genital Herpes Simplex Virus-2, on Viral Shedding and Lesions: Results of a Randomized Placebo-Controlled Trial.

Authors: Wagoner, Nicholas Van Fife, Kenneth Leone, Peter A et al.

Source: Journal of Infectious Diseases. 12/15/2018, Vol. 218 Issue 12, p1890-1899. 10p.

Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial.

Authors: Bernstein, David I. Wald, Anna Warren, Terri et al.

Source: Journal of Infectious Diseases. 3/15/2017, Vol. 215 Issue 6, p856-864. 9p.

High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial.

Authors: Ganesan, Anuradha Crum-Cianflone, Nancy Higgins, Jeanette et al.

Source: Journal of Infectious Diseases. 2011, Vol. 203 Issue 6, p756-764. 9p.

Comparisons of Causes of Death and Mortality Rates Among HIV-Infected Persons Analysis of the Pre-, Early, and Late HAART (Highly Active Antiretroviral Therapy) Eras.

Authors: Crum, Nancy F. Riffenburgh, Robert H. Wegner, Scott et al.

Source: JAIDS: Journal of Acquired Immune Deficiency Syndromes. 2/1/2006, Vol. 41 Issue 2, p194-200. 7p. 4 Charts, 1 Graph.

Safety and Immunogenicity of an Inactivated Hepatitis A Vaccine among HIV-Infected Subjects.

Authors: Wallace, Mark R. Brandt, Carolyn J. Earhart, Kenneth C. et al.

Source: Clinical Infectious Diseases. 10/15/2004, Vol. 39 Issue 8, p1207-1213. 7p.

Long-Term Efficacy of Routine Access to Antiretroviral-Resistance Testing in HIV Type 1--Infected Patients: Results of the Clinical Efficacy of Resistance Testing Trial.

Authors: Wegner, Scott A. Wallace, Mark R. Aronson, Naomi E. et al.

Source: Clinical Infectious Diseases. 3/1/2004, Vol. 38 Issue 5, p723-730. 8p.

Correlates of Human Herpesvirus-8 Seropositivity Among U.S. Military Members Recently Infected With Human Immunodeficiency Virus.

Authors: Crum, Nancy F. Wallace, Mark R. Stephan, Kevin et al.

Source: Sexually Transmitted Diseases. Sep2003, Vol. 30 Issue 9, p713-718. 6p. 6 Charts.